LeafCann Group is one of the latest companies to receive a medicinal cannabis Manufacture Licence from the Office of Drug Control (ODC).
A Manufacture Licence allows LeafCann to process and manufacture raw cannabis material into medicinal cannabis products. The disused R&D pharmaceuticals site, on the outskirts of Adelaide in South Australia, now needs to be constructed and gain Good Manufacturing Practice (GMP) certification.
This follows the companies drastic move to cancel three applications last year following their purchase of the South Australia site, as the ODC was adamant they could not change site within a working application.
LeafCann’s CEO Elisabetta Faenza said, “After several years of Company development, I am delighted that LeafCann can now begin in earnest to execute our business plan towards delivering medicinal cannabis products to the many patients whose conditions are not treated effectively by existing pharmaceuticals, and whose quality of life could be substantially improved.
“The LeafCann team’s vision is to deliver a world class outcome for the medical market by leading the sector in the development of person-centred precision medicines under GMP (Good Manufacturing Practice) production. We look forward to continued engagement with regulators and licenced industry partners to provide effective, validated medicines to those that need it most.”
The company is still waiting on a Cannabis Cultivation Licence and a Cannabis Research Licence.
